Adaptation of Clinical Practice Guideline for Assessment of Liver Fibrosis in Patients with Non Alcoholic Fatty Liver Disease in Isfahan Province

Sayed Mohammad Hosseeini, Mohammad Jafari, Marzieh Tahmasebi, Payman Adibi

Abstract


Non‑alcoholic fatty liver disease (NAFLD) refers to the presence of hepatic steatosis (accumulation of fat in the liver to over 5% of its weight) in the absence of secondary causes of fat accumulation in the liver such as excessive alcohol use. NAFLD is divided into two types: non‑alcoholic fatty liver (NAFL) and non‑alcoholic steatohepatitis (NASH). Therefore, in this clinical guideline, we sought to determine general and important policies for this disease and modify its managment approaches. We adapted this guideline for the management of NAFLD in Isfahan Province. This guideline was developed by clinical appraisal and review of the evidence, available clinical guidelines, and in consultation with members of the Isfahan Chamber of the Iranian Association of Gastroenterology and Hepatology. Biopsy is recommended as the most reliable method (gold standard) to diagnose steatohepatitis and fibrosis in patients with NAFLD. NAFLD fibrosis score (NFS) and fibrosis‑4 (FIB‑4) are recommended as the test with the highest predictive value for advanced fibrosis in patients with NAFLD compared to other serologic tests. Among the noninvasive methods used to assess liver fibrosis, transient elastography (TE) is preferable to other methods.

 

International Journal of Preventive Medicine 15():27, May 2024. | DOI: 10.4103/ijpvm.ijpvm_284_22

Corresponding Author: Dr. Mohammad Jafari

E‑mail: Jafari274@gmail.com

You can also search for this author in: PubMed Google Scholar


Keywords


Clinical practice guideline; fatty liver; guideline; liver fibrosis; NAFL; NAFLD; NASH; non‑alcoholic fatty liver disease; non‑alcoholic fatty liver; non‑alcoholic steatohepatitis

Full Text:

PDF

References


Lim JK, Flamm SL, Singh S, Falck‑Ytter YT, Gerson L,

Hirano I, et al. American Gastroenterological Association

Institute guideline on the role of elastography in the evaluation

of liver fibrosis. Gastroenterology 2017;152:1536‑43.

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K,

Rinella M, et al. The diagnosis and management of nonalcoholic

fatty liver disease: Practice guidance from the American

Association for the Study of Liver Diseases. Hepatology

;67:328‑57.

LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG,

Goh K‑L, et al. World Gastroenterology Organisation global

guidelines: Nonalcoholic fatty liver disease and nonalcoholic

steatohepatitis. J Clin Gastroenterol 2014;48:467‑73.

Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y,

et al. Evidence‑based clinical practice guidelines for nonalcoholic

fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol

;50:364‑77.

Byrne CD, Targher G. EASL–EASD–EASO Clinical Practice

Guidelines for the management of non‑alcoholic fatty liver

disease: Is universal screening appropriate? Diabetologia

;59:1141‑4.

National Institute for Health and Clinical Excellence (NICE).

Non‑Alcoholic Fatty Liver Disease (NAFLD): Assessment and

Management (NG49). London: National Institute for Health and

Clinical Excellence (NICE); 2020:1-16.

Collaboration A. The ADAPTE Process: Resource Toolkit for

Guideline Adaptation. Version 2.0. Berlin: Guideline International

Network; 2010:1-95.

Kavanagh BP. The GRADE system for rating clinical guidelines.

PLoS Med 2009;6:e1000094. doi: 10.1371/journal.pmed.

Wong VWS, Chan WK, Chitturi S, Chawla Y, Dan YY,

Duseja A, i. Asia–Pacific working party on non-alcoholic fatty

liver disease guidelines 2017—Part 1: Definition, risk factors and

assessment. J Gastroenterol Hepatol 2018;33:70‑85.

European Association for the Study of the Liver (EASL),

European Association for the Study of Diabetes (EASD),

European Association for the Study of Obesity (EASO).

EASL‑EASD‑EASO clinical practice guidelines for the

management of non‑alcoholic fatty liver disease. Obesity Facts

;9:65‑90.

Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current

guidelines for the management of non‑alcoholic fatty liver

disease: A systematic review with comparative analysis. World J

Gastroenterol 2018;24:3361‑73.

Lonardo A, Nascimbeni F, Targher G, Bernardi M, Bonino F,

Bugianesi E, et al. AISF position paper on nonalcoholic fatty

liver disease (NAFLD): Updates and future directions. Dig Liver

Dis 2017;49:471‑83.

Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM,

et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and

APRI for NAFLD-related events: A systematic review. Liver Int

;41:261‑70.

Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N,

Friedrich‑Rust M, et al. EASL Clinical Practice Guidelines on non‑invasive tests for evaluation of liver disease severity and

prognosis–2021 update. J Hepatol 2021;75:659‑89.

Rinella ME, Neuschwander‑Tetri BA, Siddiqui MS,

Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice

guidance on the clinical assessment and management of

nonalcoholic fatty liver disease. Hepatology 2023;77:1797‑835.

LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG,

Goh K‑L, et al. World Gastroenterology Organisation global

guidelines: Nonalcoholic fatty liver disease and nonalcoholic

steatohepatitis. J Clin Gastroenterol 2014;48:467-7.

Lucero C, Brown RS Jr. Noninvasive measures of liver

fibrosis and severity of liver disease. Gastroenterol Hepatol

;12:33‑40.

Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, Baumann U,

et al. Diagnosis of nonalcoholic fatty liver disease in children

and adolescents: Position paper of the ESPGHAN Hepatology

Committee. J Pediatr Gastroenterol Nutr 2012;54:700‑13.

Leroy V, Hilleret M‑N, Sturm N, Trocme C, Renversez J‑C,

Faure P, et al. Prospective comparison of six non‑invasive

scores for the diagnosis of liver fibrosis in chronic hepatitis C.

J Hepatol 2007;46:775‑82.

Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A,

Barri-Ova N, et al. Diagnostic and prognostic values of

noninvasive biomarkers of fibrosis in patients with alcoholic

liver disease. Hepatology 2009;49:97‑105.

Becker L, Salameh W, Sferruzza A, Zhang K, Chen R,

Malik R, et al. Validation of hepascore, compared with

simple indices of fibrosis, in patients with chronic hepatitis C

virus infection in United States. Clin Gastroenterol Hepatol

;7:696‑701.

Safadi R, Braun M, Francis A, Milgrom Y, Massarwa M,

Hakimian D, et al. Randomised clinical trial: A phase 2 doubleblind study of namodenoson in non-alcoholic fatty liver disease

and steatohepatitis. Aliment Pharmacol Ther 2021;54:1405‑15.

Loria P, Adinolfi L, Bellentani S, Bugianesi E, Grieco A,

Fargion S, et al. Practice guidelines for the diagnosis and

management of nonalcoholic fatty liver disease: A decalogue

from the Italian Association for the Study of the Liver (AISF)

Expert Committee. Dig Liver Dis 2010;42:272‑82.

Dietrich CF, Bamber J, Berzigotti A, Bota S, Cantisani V,

Castera L, et al. EFSUMB guidelines and recommendations

on the clinical use of liver ultrasound elastography, update

(long version). Ultraschall Med 2017;38:e16‑47.

Barr RG, Ferraioli G, Palmeri ML, Goodman ZD, Garcia‑Tsao G,

Rubin J, et al. Elastography assessment of liver fibrosis: Society

of radiologists in ultrasound consensus conference statement.

Radiology 2015;276:845‑61.

Tacke F, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M,

et al. Updated S2k clinical practice guideline on non‑alcoholic

fatty liver disease (NAFLD) issued by the German society of

gastroenterology, digestive and metabolic diseases (DGVS)–

April 2022–AWMF registration No.: 021–025. Z Gastroenterol

;60:e733‑801.

Ferraioli G, Filice C, Castera L, Choi BI, Sporea I, Wilson SR,

et al. WFUMB guidelines and recommendations for clinical use

of ultrasound elastography: Part 3: Liver. Ultrasound Med Biol

;41:1161‑79.

Li Y, Huang YS, Wang ZZ, Yang ZR, Sun F, Zhan SY, et al.

Systematic review with meta-analysis: The diagnostic accuracy

of transient elastography for the staging of liver fibrosis in

patients with chronic hepatitis B. Aliment Pharmacol Ther

;43:458‑69.

Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD.

Liver biopsy. Hepatology 2009;49:1017‑44.

Neuberger J, Patel J, Caldwell H, Davies S, Hebditch V,

Hollywood C, et al. Guidelines on the use of liver biopsy in

clinical practice from the British Society of Gastroenterology,

the Royal College of Radiologists and the Royal College of

Pathology. Gut 2020;69:1382‑403.

Wendum D, Lacombe K, Chevallier M, Callard P, Valet F,

Miailhes P, et al. Histological scoring of fibrosis and activity

in HIV‑chronic hepatitis B related liver disease: Performance

of the METAVIR score assessed on virtual slides. J Clin Pathol

;62:361‑3.